Evaluation of the efficacy of combination drugs in the treatment of broncho-obstructive syndrome in children

Introduction. Today, complex drugs are used as effective medications to relieve broncho-obstructive syndrome. Due to their composition, they can effectively influence mucociliary clearance, relieve bronchospasms, and improve sputum rheology.

Aim. To conduct a comparative evaluation of the efficacy and safety of a complex mucolytic drug and other cough treatment options in children with broncho-obstructive syndrome.

Materials and methods. A total of 167 children aged 3 to 15 years with obstructive bronchitis (mean age 7.9 ± 1.4 years) were observed. Children aged 4 to 8 years (91 children [54.5%]) represented the largest portion of the sample. The patients were divided into 2 groups: Group 1 (93 children) received Jocet® as their sole cough drug; Group 2, the control group (74 children), received a combination of mono-preparations: a bronchodilator combined with an expectorant and/or mucolytic drug.

Results. The study investigated the safety profile of a complex mucolytic drug (Jocet®). The analysis of clinical observations showed no reported adverse events in 97% of patients, which evidenced high tolerability of the drug. On Days 6–7 of treatment, the severity of clinical symptoms in Group 1 was significantly lower than in Group 2. Group 1 also demonstrated faster improvement in auscultation findings and transformation of cough into productive wet cough; Group 2 showed a similar effect on average 0.9 days later.

Conclusions. The use of Joсet® allowed to effectively and safely achieve the intended effect in children with broncho-obstructive syndrome as compared to children, who received a combination of drugs (a bronchodilator and an expectorant). Based on the study results, we would advise to include this drug in pediatric practice as an effective pathogenetic agent to treat obstructive bronchitis. 

1. Verheij T. Patients’ and doctors’ views on respiratory tract symptoms. Scand J Prim Health Care. 2002;20(4):201–202. https://doi.org/10.1080/028134302321004836.

2. Kryukov AI, Khamzalieva RB, Zakharova AF, Izotova GN. Morbidity rates and quality of outpatient care to ENT patients with ear and upper respiratory pathology. Rossiiskaya Otorinolaringologiya. 2008;(S1):117–120. (In Russ.) Available at: https://www.elibrary.ru/szvexx.

3. Kholodova IN. Treatment for upper respiratory tract infections accompanied by acute tonsillopharyngitis in children. RMJ. Medical Review. 2019;3(8):44–48. (In Russ.) Available at: https://www.rmj.ru/articles/pediatriya/Lechenie_infekciy_verhnih_dyhatelynyh_putey_soprovoghdayuschihsya_razvitiem_ostrogo_tonzillofaringita_u_detey/.

4. Egorov AYu. The problem of bacterial complications post respiratory viral infections. MIR J. 2018;5(1):1–11. (In Russ.) https://doi.org/10.18527/2500-2236-2018-5-1-1-11.

5. Geppe NA, Glukhova MV, Denisova AR, Kolosova NG, Shatalina SI, Shakhnazarova MD. Acute respiratory disorders in children: Efficacy of mucolytic agents. Doktor.Ru. 2015;(13):59–63. (In Russ.) Available at: https://journaldoctor.ru/catalog/pediatriya/effektivnost-mukoliticheskoy-terapii-pri-ostrykh-respiratornykh-zabolevaniyakh-u-detey/.

6. Denisova AR, Maksimov ML. Acute respiratory viral infections: etiology, diagnosis, modern view of treatment. RMJ. Medical Review. 2018;(1):99–103. (In Russ.) Available at: https://www.rmj.ru/articles/infektsionnye_bolezni/Ostrye_respiratornye_virusnye_infekcii_etiologiya_diagnostika_sovremennyy_vzglyad_na_lechenie/.

7. Geppe NA, Dronov IA, Bayandina GN. Approaches to treating acute respiratory infections in children. Doctor.Ru. 2017;(4):14–18. (In Russ.) Available at: https://journaldoctor.ru/catalog/pediatriya/terapevticheskaya-taktika/.

8. Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG. Impact of Mucolytic Agents on COPD Exacerbations: A Pair- wise and Network Metaanalysis. COPD. 2017;14(5):552–563. https://doi.org/10.1080/15412555.2017.1347918.

9. Geppe NA, Malakhov AB, Zaytseva OV, Degtyareva MV, Ilyenkova NA, Kalyuzhin OV et al. Controversial and unresolved issues in the treatment of cough in children in outpatient practice. Pediatrics. Consilium Medicum. 2017;(4):40–45. (In Russ.) Available at: https://www.elibrary.ru/ymfkou.

10. Mizernitskiy YL, Dorovskaya NL, Melnikova IM. Combination therapy for cough and bronchial obstruction in childhood. Meditsinskiy Sovet. 2019;(17):83–89. (In Russ.) https://doi.org/10.21518/2079-701X-2019-17-83-89.

11. Mizernitskiy YL, Melnikova IM. Persistent and prolonged cough in children: differential diagnosis and treatment algorithms. Meditsinskiy Sovet. 2019;(17):58–75. (In Russ.) https://doi.org/10.21518/2079-701X-2019-17-58-75.

12. Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Efficacy and safety profile of mucolytic/ antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N- acetylcysteine. Respir Res. 2019;20(1):104. https://doi.org/10.1186/s12931-019-1078-y.

13. КKolosova NG, Shatalina SI. Antitussive drugs in children’s practice. Meditsinskiy Sovet. 2017;(9):76–79. (In Russ.) https://doi.org/10.21518/2079-701X-2017-976-79.

14. Ovchinnikov AIu, Miroshnichenko NA, Mitiuk AM, Ryabinin VA, Gorban DG. The new possibilities for the treatment of chronic cough associated with postnasal drip. Vestnik Oto- Rino- Laringologii. 2017;82(2):60–64. (In Russ.) https://doi.org/10.17116/otorino201782260-64.

15. Pikuza OI, Faizullina RA, Zakirova AM, Shoshina NK. Cough: from symptom to syndrome, diagnosis. Practical Medicine. 2010;(6):34–37. (In Russ.) Available at: https://cyberleninka.ru/article/n/kashel-ot-simptoma-k-sindromu-diagnozu.

16. Melnikova IM, Minernitsky YL. Individually orientated choice of mucolytic drug for coughing in a child with acute respiratory viral infections. Meditsinskiy Sovet. 2019;(2):224–230. (In Russ.) https://doi.org/10.21518/2079-701X-2019-2-224-230.

17. Klyachkina IL, Sinopalnikov AI. Fixed- dose combinations of mucoactive drugs in the cough treatment program. Prakticheskaya Pulʹmonologiya. 2015;(1):74–82. (In Russ.) Available at: http://www.atmosphere-ph.ru/modules/Magazines/articles/pulmo/PP_1_2015_74.pdf.

18. Knyazheskaya NP, Bokov EV, Tatarskiy AR. Ascoril combination drug in the treatment of cough and bronchial obstruction. RMJ. 2013;(7):368. (In Russ.) Available at: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Kombinirovannyy_preparat_Askoril_v_terapii_kashlya_i_bronhoobstrukcii/.

19. Sergienko AV, Ivashev MN. Pharmacodynamic synergism of Ascoril. International Journal of Experimental Education. 2015;(11- 1):38. (In Russ.) Available at:https://www.expeducation.ru/ru/article/view?id=8286.

20. Ullmann N, Caggiano S, Cutrera R. Salbutamol and around. Ital J Pediatr. 2015;41(Suppl 2):A74. https://doi.org/10.1186/1824-7288-41-S2-A74.

21. Yuan J, Lu ZK, Zhang Y, Wu J, Love BL, Schulz RM. Clinical outcomes of levalbuterol versus racemic albuterol in pediatric patients with asthma: Propensity score matching approach in a medicaid population. Pediatr Pulmonol. 2017;52(4):516–523. https://doi.org/10.1002/ppul.23565.